The effect of crocin on MS

The effect of crocin on inflammation factors,DNA damage and biomarkers of oxidative injury in the blood of patients with multiple sclerosis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016092713194N2

Enrollment

Registered

2017-04-30

Start date

2017-05-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis (of): NOS brain stem cord disseminated generalized

Interventions

Intervention 1: Intervention group: Patients receiving 30 mg of crocin twice daily. Intervention 2: Control group: patients receiving placebotwice daily.

Treatment - Drugs

Placebo

Intervention group: Patients receiving 30 mg of crocin twice daily.

Control group: patients receiving placebotwice daily.

Eligibility

Sex/Gender

All

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: Recently diagnosed relapsing-remitting MS patients; Patients between 20-40 years old exclusion criteria: Receiving immunomodulatory drugs such as interferons; Diabetes; Chronic disease like cardiac, liver or kidney disease; Smoking; Pregnancy and lactation; EDSS>4; Any rheumatologic disease or vasculitis; History of hypersensitivity to saffron

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
IL-17. Timepoint: first week and fourth week. Method of measurement: ELISA.;TNF-a. Timepoint: first week and fourth week. Method of measurement: ELISA.;DNA damage. Timepoint: first week and fourth week. Method of measurement: ELISA.;Lipid peroxidation. Timepoint: first week and fourth week. Method of measurement: ELISA.;Total antioxidant capacity. Timepoint: first week and fourth week. Method of measurement: spectrophotometery.;Thiol groups. Timepoint: first week and fourth week. Method of measurement: Spectrophotometery.	—

Measure

Time frame

IL-17. Timepoint: first week and fourth week. Method of measurement: ELISA.;TNF-a. Timepoint: first week and fourth week. Method of measurement: ELISA.;DNA damage. Timepoint: first week and fourth week. Method of measurement: ELISA.;Lipid peroxidation. Timepoint: first week and fourth week. Method of measurement: ELISA.;Total antioxidant capacity. Timepoint: first week and fourth week. Method of measurement: spectrophotometery.;Thiol groups. Timepoint: first week and fourth week. Method of measurement: Spectrophotometery.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAkram Ranjbar

Hamedan University of Medical Sciences

Akranjbar2015@gmail.com+98 81 3838 1591

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026